<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03056378</url>
  </required_header>
  <id_info>
    <org_study_id>NYBC-0088</org_study_id>
    <nct_id>NCT03056378</nct_id>
  </id_info>
  <brief_title>POOLED Red Blood Cells Prepared From Pooling 5 Leukoreduced, Irradiated RBC Units</brief_title>
  <acronym>Pooled RBCs</acronym>
  <official_title>Phase I Clinical Trial of Pooled Red Blood Cells for Transfusion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York Blood Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Westchester Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>New York Blood Center</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine the safety of pooled red blood cells (RBCs) compared
      to standard leukoreduced RBC products stored in additive solution. The primary objective is
      to determine if there is no significant difference in transfusion associated adverse events
      in POOLED-RBCs compared to standard RBC product groups. Secondarily to determine if there are
      no significant differences in new antibody and new positive direct antiglobulin test (DAT)
      formation in the POOLED-RBCs compared to standard RBC product groups.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This research study is enrolling subjects who are receiving RBC (red blood cell) blood
      transfusions as part of their treatment. In this study, we are testing a new way of preparing
      RBC units (pooled RBC units) for transfusion compared to the standard RBC units. We are
      testing this because blood transfusions may be associated with side effects that may be
      harmful. We have developed a new way to process RBC for transfusion to try and reduce some of
      those side effects.

      The pooled RBC units will be made by sterilely pooling five (5) single RBC units into one
      container where the blood will be mixed together, and then separated into five individual RBC
      units, ready to be used for transfusion. The purpose of the study is to determine the safety
      of the blood prepared in this new way compared to standard RBC products.

      The primary objective is to determine if there is no significant difference in transfusion
      associated adverse events in POOLED-RBCs compared to standard RBC product groups. Secondarily
      to determine if there are no significant differences in new antibody and new positive direct
      antiglobulin test (DAT) formation in the POOLED-RBCs compared to standard RBC product groups.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2017</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">February 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Quantitation of adverse events</measure>
    <time_frame>60 day endpoint</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quantitation of RBC alloantibody formation</measure>
    <time_frame>15 and 30 minutes post-transfusion</time_frame>
    <description>Quantitation of new DAT formation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Transfusion Reaction</condition>
  <condition>Anemia</condition>
  <arm_group>
    <arm_group_label>Pooled RBCs</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Transfusion of an investigational transfusion blood component: POOLED-RBCs Phenotype matched/ compatible for ABO, D, C, E, and K (blood type of pool will be match patient's type), leukoreduced, and irradiated</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard RBCs</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Transfusion of standard transfusion blood component: additive solution leukoreduced, irradiated RBC product Phenotype matched/ compatible for ABO, D, C, E, and K (blood type of pool will be match patient's type)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Standard RBCs</intervention_name>
    <description>Transfusion of standard pRBCs that are matched for C, E and K</description>
    <arm_group_label>Pooled RBCs</arm_group_label>
    <arm_group_label>Standard RBCs</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age&gt;= 18 years

          -  Hematology/ oncology or other chronic transfusion dependent patients

          -  Patients who are in need of transfusion due to low hemoglobin level (&lt;8 gm/dl)

          -  Patients who only require one or two transfusion episode of 1-2 RBC units each during
             60 day period

          -  Currently not planning to be pregnant during the study period

        Exclusion Criteria:

          -  Previously identified alloantibodies (other than to D, C, E and K)

          -  Positive direct antiglobulin test, currently or within the last year

          -  Emergency transfusion

          -  Patients &lt; 18 years old

          -  Need for specialized products, such as washed

          -  Patients involved in other RBC transfusion clinical trial

          -  Currently or planning to be pregnant within the proposed study period
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Beth Shaz, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>New York Blood Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Beth Shaz, M.D.</last_name>
    <phone>212-570-3460</phone>
    <email>BShaz@nybc.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Bruce Sachais, M.D., Ph.D.</last_name>
    <phone>(212) 699-5154</phone>
    <email>BSachais@nybc.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Westchester Medical Center/New York Medical College</name>
      <address>
        <city>Valhalla</city>
        <state>New York</state>
        <zip>10595</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alexandra Jimenez, M.D.</last_name>
      <phone>917-359-6451</phone>
      <email>AJimenez2@nybc.org</email>
    </contact>
    <contact_backup>
      <last_name>Bruce Sachais, M.D.</last_name>
      <phone>212.699.5154</phone>
      <email>BSachais@nybc.org</email>
    </contact_backup>
    <investigator>
      <last_name>Mitchell Cairo, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bruce Sachais, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alexandra Jimenez, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.cdc.gov/nhsn/pdfs/biovigilance/bv-hv-protocol-current.pdf</url>
    <description>National Healthcare Safety Network Biovigilance component Hemovigilance module Surveillance Protocol: Center for Disease Control Prevention, ed.2017</description>
  </link>
  <reference>
    <citation>Hendrickson JE, Hillyer CD. Noninfectious serious hazards of transfusion. Anesth Analg. 2009 Mar;108(3):759-69. doi: 10.1213/ane.0b013e3181930a6e. Review.</citation>
    <PMID>19224780</PMID>
  </reference>
  <reference>
    <citation>Tobian AA, Fuller AK, Uglik K, Tisch DJ, Borge PD, Benjamin RJ, Ness PM, King KE. The impact of platelet additive solution apheresis platelets on allergic transfusion reactions and corrected count increment (CME). Transfusion. 2014 Jun;54(6):1523-9; quiz 1522. doi: 10.1111/trf.12498. Epub 2013 Nov 19.</citation>
    <PMID>24251374</PMID>
  </reference>
  <reference>
    <citation>Hess JR; Biomedical Excellence for Safer Transfusion (BEST) Collaborative. Scientific problems in the regulation of red blood cell products. Transfusion. 2012 Aug;52(8):1827-35. doi: 10.1111/j.1537-2995.2011.03511.x. Epub 2012 Jan 9. Review.</citation>
    <PMID>22229278</PMID>
  </reference>
  <reference>
    <citation>Marthur A, Stassinopoulos A, Hess JR, Narla M, Shaz BH. Effects of pooling multiple red blood cell units to improve storage. Blood 2012;120:3437</citation>
  </reference>
  <reference>
    <citation>Mathur A, Chowdhury R, Hillyer CD, Mitchell WB, Shaz BH. Storage characteristics of multiple-donor pooled red blood cells compared to single-donor red blood cell units. Transfusion. 2016 Dec;56(12):2941-2947. doi: 10.1111/trf.13866. Epub 2016 Oct 5.</citation>
    <PMID>27704557</PMID>
  </reference>
  <reference>
    <citation>Lasalle-Williams M, Nuss R, Le T, Cole L, Hassell K, Murphy JR, Ambruso DR. Extended red blood cell antigen matching for transfusions in sickle cell disease: a review of a 14-year experience from a single center (CME). Transfusion. 2011 Aug;51(8):1732-9. doi: 10.1111/j.1537-2995.2010.03045.x. Epub 2011 Feb 18.</citation>
    <PMID>21332724</PMID>
  </reference>
  <reference>
    <citation>Verduin EP, Brand A, Schonewille H. Is female sex a risk factor for red blood cell alloimmunization after transfusion? A systematic review. Transfus Med Rev. 2012 Oct;26(4):342-53, 353.e1-5. doi: 10.1016/j.tmrv.2011.12.001. Epub 2012 Jan 13. Review.</citation>
    <PMID>22244869</PMID>
  </reference>
  <reference>
    <citation>Custer B, Agapova M, Martinez RH. The cost-effectiveness of pathogen reduction technology as assessed using a multiple risk reduction model. Transfusion. 2010 Nov;50(11):2461-73. doi: 10.1111/j.1537-2995.2010.02704.x.</citation>
    <PMID>20497512</PMID>
  </reference>
  <reference>
    <citation>Sweeney JD, Kouttab NM, Holme S, Kurtis JD, Cheves TA, Nelson EJ. Prestorage pooled whole-blood-derived leukoreduced platelets stored for seven days, preserve acceptable quality and do not show evidence of a mixed lymphocyte reaction. Transfusion. 2004 Aug;44(8):1212-9.</citation>
    <PMID>15265126</PMID>
  </reference>
  <reference>
    <citation>Thiele T, Heddle N, Greinacher A. Donor exposures in recipients of pooled platelet concentrates. N Engl J Med. 2013 Jan 31;368(5):487-9. doi: 10.1056/NEJMc1213383.</citation>
    <PMID>23363522</PMID>
  </reference>
  <reference>
    <citation>Zou S, Stramer SL, Dodd RY. Donor testing and risk: current prevalence, incidence, and residual risk of transfusion-transmissible agents in US allogeneic donations. Transfus Med Rev. 2012 Apr;26(2):119-28. doi: 10.1016/j.tmrv.2011.07.007. Epub 2011 Aug 25. Review.</citation>
    <PMID>21871776</PMID>
  </reference>
  <reference>
    <citation>Stramer SL, Notari EP, Krysztof DE, Dodd RY. Hepatitis B virus testing by minipool nucleic acid testing: does it improve blood safety? Transfusion. 2013 Oct;53(10 Pt 2):2449-58. doi: 10.1111/trf.12213. Epub 2013 Apr 23.</citation>
    <PMID>23607261</PMID>
  </reference>
  <reference>
    <citation>Levin AE, Williamson PC, Bloch EM, Clifford J, Cyrus S, Shaz BH, Kessler D, Gorlin J, Erwin JL, Krueger NX, Williams GV, Penezina O, Telford SR 4th, Branda JA, Krause PJ, Wormser GP, Schotthoefer AM, Fritsche TR, Busch MP. Serologic screening of United States blood donors for Babesia microti using an investigational enzyme immunoassay. Transfusion. 2016 Jul;56(7):1866-74. doi: 10.1111/trf.13618. Epub 2016 May 25.</citation>
    <PMID>27224258</PMID>
  </reference>
  <reference>
    <citation>Levin AE, Williamson PC, Erwin JL, Cyrus S, Bloch EM, Shaz BH, Kessler D, Telford SR 3rd, Krause PJ, Wormser GP, Ni X, Wang H, Krueger NX, Caglioti S, Busch MP. Determination of Babesia microti seroprevalence in blood donor populations using an investigational enzyme immunoassay. Transfusion. 2014 Sep;54(9):2237-44. doi: 10.1111/trf.12763. Epub 2014 Jul 4.</citation>
    <PMID>24995863</PMID>
  </reference>
  <reference>
    <citation>Tormey CA, Sweeney JD, Champion MH, Pisciotto PT, Snyder EL, Wu Y. Analysis of transfusion reactions associated with prestorage-pooled platelet components. Transfusion. 2009 Jun;49(6):1242-7. doi: 10.1111/j.1537-2995.2009.02128.x. Epub 2009 Mar 23.</citation>
    <PMID>19389029</PMID>
  </reference>
  <reference>
    <citation>Daurat A, Roger C, Gris J, Daurat G, Feissel M, Le Manach Y, Lefrant J, Muller L. Apheresis platelets are more frequently associated with adverse reactions than pooled platelets both in recipients and in donors: a study from French hemovigilance data. Transfusion. 2016 Jun;56(6):1295-303. doi: 10.1111/trf.13475. Epub 2016 Jan 26.</citation>
    <PMID>26814984</PMID>
  </reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 13, 2017</study_first_submitted>
  <study_first_submitted_qc>February 14, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 17, 2017</study_first_posted>
  <last_update_submitted>May 3, 2017</last_update_submitted>
  <last_update_submitted_qc>May 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Transfusion Reaction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

